Abstract
The term ‘epidemic’ has evolved dramatically from its first use by Homer and Hippocrates, through the Middle Ages when it defined the rapid propagation of diseases like the plague, to the 19th century when it was used to describe infectious diseases, and later in the 20th century where the term is applied to noninfectious diseases such as obesity and type 2 diabetes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Martin PMV, Martin-Granel E. 2,500-year evolution of the term epidemic. Emerg Infect Dis. 2006:12:976-980. wwwnc.cdc.gov/eid/article/12/6/pdfs/05-1263.pdf. Accessed January 5, 2015.
International Diabetes Federation. Diabetes: facts and figures. www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Accessed October 5, 2015.
DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773-795.
American Diabetes Association. Standards of medical care in diabetes 2014. Diabetes Care. 2014;37(suppl 1):S14-S80.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
Patel A, MacMahon S, Chalmers J, et al. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
International Diabetes Federation (IDF). IDF Clinical Guidelines: Global Guidelines for Type 2 Diabetes. 2011/2012. www.idf.org/guidelines. Accessed October 5, 2015.
Handelsman Y, Machanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. AACE Diabetes Care Plan Guidelines. Endocr Pract. 2011;17(suppl 2):1-53. www.aace.com/files/dm-guidelines-ccp.pdf. Accessed October 5, 2015.
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819-837.
Scirica BM1, Bhatt DL, Braunwald E, et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J. 2011;162:818-825.
White WB, Bakris GL, Bergenstal RM, et al. EXamination of cArdiovascular outcoMes with alogliptin versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J. 2011;162:620-626.
Green JB, Bethel MA, Paul SK, et al. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. Am Heart J. 2013;166:983-989.
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA). http://clinicaltrials.gov/ct2/show/NCT01147250. Accessed October 5, 2015.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Mudaliar, S., Henry, R.R. (2016). Introduction and disease overview. In: Gough, S. (eds) Handbook of Incretin-based Therapies in Type 2 Diabetes. Adis, Cham. https://doi.org/10.1007/978-3-319-08982-9_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-08982-9_1
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-08981-2
Online ISBN: 978-3-319-08982-9
eBook Packages: MedicineMedicine (R0)